Abstract
The past 5 years have seen an unprecedented rate of discovery of genes that cause rare diseases and with it a commensurate increase in the number of diagnosable but nevertheless untreatable disorders. Here, we discuss the increasing opportunity for diagnosis and therapy of rare diseases and how to tackle the associated challenges.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Clinical implementation of RNA sequencing for Mendelian disease diagnostics
Genome Medicine Open Access 05 April 2022
-
Clinical development innovation in rare diseases: lessons learned and best practices from the DevelopAKUre consortium
Orphanet Journal of Rare Diseases Open Access 14 December 2021
-
The impact of rarity in NICE’s health technology appraisals
Orphanet Journal of Rare Diseases Open Access 13 May 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Boycott, K. M. et al. International cooperation to enable the diagnosis of all rare genetic diseases. Am. J. Hum. Genet. 10, 695–705 (2017).
Giannuzzi, V. et al. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen. Orphanet J. Rare Dis. 12, 64–75 (2017).
Dawkins, H. J. S. et al. Progress in rare diseases research 2010-2016: an IRDiRC perspective. Clin. Transl Sci. http://dx.doi.org/10.1111/cts.12501 (2017).
Meekings, K. N., Williams, C. S. & Arrowsmith, J. E. Orphan drug development: an economically viable strategy for biopharma R&D. Drug Disc. Today 17, 660–664 (2012).
Austin, C. P. et al. Future of rare diseases research 2017–2027: an IRDiRC perspective. Clin. Transl Sci. http://dx.doi.org/10.1111/cts.12500 (2017).
Acknowledgements
The authors would like to thank A. MacKenzie for helpful discussions, and H. Howley and T. Hartley for editing the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K.M.B. declares no competing interests. D.A. is a full-time employee of Chiesi Farmaceutici S.p.A.
Related links
Rights and permissions
About this article
Cite this article
Boycott, K., Ardigó, D. Addressing challenges in the diagnosis and treatment of rare genetic diseases. Nat Rev Drug Discov 17, 151–152 (2018). https://doi.org/10.1038/nrd.2017.246
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.246
This article is cited by
-
Development of vascular disease models to explore disease causation and pathomechanisms of rare vascular diseases
Seminars in Immunopathology (2022)
-
Clinical implementation of RNA sequencing for Mendelian disease diagnostics
Genome Medicine (2022)
-
Clinical development innovation in rare diseases: lessons learned and best practices from the DevelopAKUre consortium
Orphanet Journal of Rare Diseases (2021)
-
The impact of rarity in NICE’s health technology appraisals
Orphanet Journal of Rare Diseases (2021)
-
Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook
Nature Reviews Drug Discovery (2020)
